Listing 3 - Actual negotiations

Indication:

Large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), high grade B-cell lymphoma, Epstein-Barr virus-positive (EBV+) DLBCL NOS, and T-cell/histiocyte rich LBCL, previously untreated in adult patients. (in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP))

Indication:

Unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement and a ECOG performance status of 0 to 2, Previously treated, in adults

Indication:

Generalized myasthenia gravis (gMG)

Indication:

Prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) in adult patients who have received at least one androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy.

Indication:

Rheumatoid Arthritis

Indication:

Crohn's disease

Indication:

Ulcerative Colitis

Indication:

Multiple Indications

Indication:

Neurofibromatosis type 1 in pediatric patients aged 2 years and above, who have symptomatic, inoperable plexiform neurofibromas

Indication:

In combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma.